MSME Pharma Capital Subsidy (RPTUAS) — 10–20% Support for Upgrading to Revised Schedule M and WHO-GMP
Video Explanation & Insights
Capital subsidy for MSME pharma and drug units: up to ₹2 crore
2 videos on this topic
Why the scheme exists
India supplies medicines and active pharmaceutical ingredients to the whole world, but many of its small and medium formulation and bulk-drug units run on older plant that does not meet the Revised Schedule M of the Drugs and Cosmetics Rules or WHO Good Manufacturing Practice. The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, revamped its Pharmaceuticals Technology Upgradation Assistance Scheme to pay a capital subsidy to MSME pharma units that invest in upgrading — better regulatory compliance, higher quality standards and, through them, larger export volumes against competitors such as China.
The subsidy is a percentage of eligible capital expenditure incurred on or after 1 January 2024 for upgrading production, utilities and quality control to the Revised Schedule M and WHO-GMP standards, graded by the unit's turnover. Investments made before that date do not qualify; investments up to the scheme's closing date do.
Who qualifies and what is paid
| Item | Rule | Notes |
|---|---|---|
| Applicant | Pharmaceutical manufacturing unit registered as an MSME (Udyam) | The 2025 revision of MSME definitions brings most units within reach |
| Activity | Formulations, bulk drugs / APIs and nutraceuticals manufacturing | Trading and marketing companies are not eligible |
| Purpose | Upgrading to Revised Schedule M and / or WHO-GMP standards | Capex must serve compliance and quality upgrade |
| Date | Capital expenditure incurred on or after 1 January 2024 | Earlier capex is excluded |
| Subsidy | 10% to 20% of eligible capex, higher for smaller units — 20% for turnover below ₹50 crore, 15% for ₹50–250 crore, 10% for ₹250–500 crore | Subject to a per-unit ceiling (₹2 crore as explained in the video) |
| Window | Investment up to 31 December 2026 as explained in the video | Check the Department's current notification |
Eligible capital expenditure
Production
- •Production machinery and equipment
- •Clean-room facilities and partitions
- •HVAC systems
- •Water and steam utilities (purified water, WFI, pure steam)
Quality
- •Testing laboratory equipment
- •Stability chambers
- •Quality-control and documentation systems
- •Air and water purification systems
Compliance areas under Schedule M
- •Building and premises upgrades
- •Personnel hygiene and training infrastructure
- •Documentation and record keeping
- •Quality assurance systems
Revised Schedule M and WHO-GMP
| Revised Schedule M | WHO-GMP | |
|---|---|---|
| Issued by | CDSCO under the Drugs and Cosmetics Rules (national) | World Health Organization (international) |
| Covers | Premises, equipment, quality control, personnel, water and air systems, documentation, clean rooms | Good manufacturing practice for export-oriented and WHO-prequalified supply |
| Why it matters | Mandatory for domestic manufacture; deadlines for MSMEs were extended to give time to upgrade | Required by many importing countries and institutional buyers |
| Scheme link | Capex to reach either or both standards qualifies | Capex to reach either or both standards qualifies |
Documents for the claim
Evaluation and release
- 1Step 1 — Technical feasibility: the project report establishes how each investment moves the unit to Revised Schedule M / WHO-GMP.
- 2Step 2 — Expenditure verification: invoices, quotations and bank payments are matched to the fixed-asset schedule in the audited balance sheet.
- 3Step 3 — Compliance documentation: the unit's standard status before the upgrade and after it is evidenced.
- 4Step 4 — Application on the Department of Pharmaceuticals portal with CA certificates; scrutiny and queries.
- 5Step 5 — Approval and release of the subsidy to the unit's bank account.
Common mistakes
- •Claiming capex dated before 1 January 2024.
- •Machinery that does not serve Schedule M or WHO-GMP compliance — general expansion is not the purpose.
- •Payments in cash or from accounts not belonging to the unit, which cannot be verified.
- •Second-hand equipment or expenditure not appearing in the audited fixed-asset schedule.
- •Waiting for the deadline — the evaluation needs documents that take weeks to assemble.
Pharma capital subsidy: questions units ask
The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, under its Revamped Pharmaceuticals Technology Upgradation Assistance Scheme.
MSME pharma manufacturing units — formulations, bulk drugs / APIs and nutraceuticals — upgrading to Revised Schedule M and / or WHO-GMP standards.
10% to 20% of eligible capital expenditure, higher for smaller units, subject to a per-unit ceiling (₹2 crore as explained in the video).
Production machinery, HVAC, clean rooms, water and steam utilities, testing laboratories, stability chambers and related compliance infrastructure bought on or after 1 January 2024.
The video cites 31 December 2026 as the last date for eligible investment; confirm the current notification of the Department.
PLI for pharmaceuticals is a separate incentive on incremental sales for larger manufacturers; a unit may participate in both subject to each scheme's rules.
Map the capex to eligible heads, prepare the project report and CA certificates, assemble compliance evidence and file and follow the claim.